vs
Cadre Holdings, Inc.（CDRE）与CollPlant Biotechnologies Ltd（CLGN）财务数据对比。点击上方公司名可切换其他公司
Cadre Holdings, Inc.的季度营收约是CollPlant Biotechnologies Ltd的934.2倍（$167.2M vs $179.0K）。Cadre Holdings, Inc.净利率更高（7.0% vs -1869.8%，领先1876.9%）。Cadre Holdings, Inc.同比增速更快（-5.0% vs -28.1%）
Cadre Holdings, Inc.是美国金融科技企业，面向个人及机构客户提供房地产投资项目直投渠道，覆盖纽约等地的商业地产。公司打造的投资平台支持投资者自主选择参与的具体交易项目，且投资门槛远低于全额收购物业所需资金，让不动产投资变得更接近股票交易，获得财经媒体的广泛认可。
CollPlant Biotechnologies是一家再生医疗企业，依托专有的植物源人胶原蛋白技术，开发并商业化伤口护理、软组织修复、医美领域的创新产品，主要面向北美、欧洲及以色列市场，服务皮肤科、骨科和医美领域的医疗从业者。
CDRE vs CLGN — 直观对比
营收规模更大
CDRE
是对方的934.2倍
$179.0K
营收增速更快
CDRE
高出23.1%
-28.1%
净利率更高
CDRE
高出1876.9%
-1869.8%
损益表 — Q4 2025 vs Q2 2025
| 指标 | | |
|---|---|---|
| 营收 | $167.2M | $179.0K |
| 净利润 | $11.7M | $-3.3M |
| 毛利率 | 43.4% | -3.9% |
| 营业利润率 | 12.2% | -1775.4% |
| 净利率 | 7.0% | -1869.8% |
| 营收同比 | -5.0% | -28.1% |
| 净利润同比 | -9.6% | 20.5% |
| 每股收益（稀释后） | $0.22 | $0.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDRECLGN
| Q4 25 | $167.2M | — | ||
| Q3 25 | $155.9M | — | ||
| Q2 25 | $157.1M | $179.0K | ||
| Q1 25 | $130.1M | — | ||
| Q4 24 | $176.0M | — | ||
| Q3 24 | $109.4M | — | ||
| Q2 24 | $144.3M | $249.0K | ||
| Q1 24 | $137.9M | — |
净利润CDRECLGN
| Q4 25 | $11.7M | — | ||
| Q3 25 | $10.9M | — | ||
| Q2 25 | $12.2M | $-3.3M | ||
| Q1 25 | $9.2M | — | ||
| Q4 24 | $13.0M | — | ||
| Q3 24 | $3.7M | — | ||
| Q2 24 | $12.6M | $-4.2M | ||
| Q1 24 | $6.9M | — |
毛利率CDRECLGN
| Q4 25 | 43.4% | — | ||
| Q3 25 | 42.7% | — | ||
| Q2 25 | 40.9% | -3.9% | ||
| Q1 25 | 43.1% | — | ||
| Q4 24 | 43.9% | — | ||
| Q3 24 | 36.6% | — | ||
| Q2 24 | 40.6% | -115.3% | ||
| Q1 24 | 41.8% | — |
营业利润率CDRECLGN
| Q4 25 | 12.2% | — | ||
| Q3 25 | 12.0% | — | ||
| Q2 25 | 9.3% | -1775.4% | ||
| Q1 25 | 10.4% | — | ||
| Q4 24 | 16.7% | — | ||
| Q3 24 | 5.0% | — | ||
| Q2 24 | 13.8% | -1769.5% | ||
| Q1 24 | 8.7% | — |
净利率CDRECLGN
| Q4 25 | 7.0% | — | ||
| Q3 25 | 7.0% | — | ||
| Q2 25 | 7.8% | -1869.8% | ||
| Q1 25 | 7.1% | — | ||
| Q4 24 | 7.4% | — | ||
| Q3 24 | 3.3% | — | ||
| Q2 24 | 8.7% | -1690.8% | ||
| Q1 24 | 5.0% | — |
每股收益（稀释后）CDRECLGN
| Q4 25 | $0.22 | — | ||
| Q3 25 | $0.27 | — | ||
| Q2 25 | $0.30 | $0.28 | ||
| Q1 25 | $0.23 | — | ||
| Q4 24 | $0.32 | — | ||
| Q3 24 | $0.09 | — | ||
| Q2 24 | $0.31 | $0.37 | ||
| Q1 24 | $0.18 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $122.9M | $11.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $317.8M | $12.5M |
| 总资产 | $770.0M | $17.4M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CDRECLGN
| Q4 25 | $122.9M | — | ||
| Q3 25 | $150.9M | — | ||
| Q2 25 | $137.5M | $11.4M | ||
| Q1 25 | $133.4M | — | ||
| Q4 24 | $124.9M | — | ||
| Q3 24 | $93.0M | — | ||
| Q2 24 | $105.9M | $18.9M | ||
| Q1 24 | $87.1M | — |
股东权益CDRECLGN
| Q4 25 | $317.8M | — | ||
| Q3 25 | $340.4M | — | ||
| Q2 25 | $332.5M | $12.5M | ||
| Q1 25 | $317.6M | — | ||
| Q4 24 | $311.5M | — | ||
| Q3 24 | $300.3M | — | ||
| Q2 24 | $299.4M | $20.7M | ||
| Q1 24 | $270.7M | — |
总资产CDRECLGN
| Q4 25 | $770.0M | — | ||
| Q3 25 | $792.1M | — | ||
| Q2 25 | $794.4M | $17.4M | ||
| Q1 25 | $656.3M | — | ||
| Q4 24 | $652.7M | — | ||
| Q3 24 | $616.6M | — | ||
| Q2 24 | $620.6M | $26.6M | ||
| Q1 24 | $599.4M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $21.3M | — |
| 自由现金流经营现金流 - 资本支出 | $18.0M | — |
| 自由现金流率自由现金流/营收 | 10.7% | — |
| 资本支出强度资本支出/营收 | 2.0% | — |
| 现金转化率经营现金流/净利润 | 1.81× | — |
| 过去12个月自由现金流最近4个季度 | $56.8M | — |
8季度趋势，按日历期对齐
经营现金流CDRECLGN
| Q4 25 | $21.3M | — | ||
| Q3 25 | $22.5M | — | ||
| Q2 25 | $2.6M | — | ||
| Q1 25 | $17.4M | — | ||
| Q4 24 | $23.7M | — | ||
| Q3 24 | $-5.2M | — | ||
| Q2 24 | $11.1M | — | ||
| Q1 24 | $2.1M | — |
自由现金流CDRECLGN
| Q4 25 | $18.0M | — | ||
| Q3 25 | $21.6M | — | ||
| Q2 25 | $1.2M | — | ||
| Q1 25 | $16.1M | — | ||
| Q4 24 | $22.4M | — | ||
| Q3 24 | $-6.2M | — | ||
| Q2 24 | $9.1M | — | ||
| Q1 24 | $794.0K | — |
自由现金流率CDRECLGN
| Q4 25 | 10.7% | — | ||
| Q3 25 | 13.9% | — | ||
| Q2 25 | 0.7% | — | ||
| Q1 25 | 12.4% | — | ||
| Q4 24 | 12.7% | — | ||
| Q3 24 | -5.7% | — | ||
| Q2 24 | 6.3% | — | ||
| Q1 24 | 0.6% | — |
资本支出强度CDRECLGN
| Q4 25 | 2.0% | — | ||
| Q3 25 | 0.5% | — | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 1.0% | — | ||
| Q4 24 | 0.7% | — | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | 1.4% | — | ||
| Q1 24 | 1.0% | — |
现金转化率CDRECLGN
| Q4 25 | 1.81× | — | ||
| Q3 25 | 2.05× | — | ||
| Q2 25 | 0.21× | — | ||
| Q1 25 | 1.88× | — | ||
| Q4 24 | 1.83× | — | ||
| Q3 24 | -1.43× | — | ||
| Q2 24 | 0.89× | — | ||
| Q1 24 | 0.31× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDRE
| U.s.state And Local Agencies | $72.7M | 43% |
| Other | $48.6M | 29% |
| U.s.Federal Agencies | $31.6M | 19% |
| Commercial | $12.0M | 7% |
CLGN
暂无分部数据
